Literature DB >> 17332420

Juvenile metachromatic leukodystrophy: understanding the disease and implications for nursing care.

Catherine Barrell1.   

Abstract

Hematopoietic stem cell transplants are increasingly being performed in attempt to halt the progression of juvenile metachromatic leukodystrophy, which is a rare neurodegenerative disease. Children who are diagnosed with metachromatic leukodystrophy are not commonly cared for by nurses who specialize in pediatric stem cell transplants. This article provides nurses with insight about this disease and serves as a guide for nursing care of this patient population during hematopoietic stem cell transplant. The case study highlights the complexities of care of this population while illustrating many of the unique care needs of patients with metachromatic leukodystrophy undergoing hematopoietic stem cell transplant. The article provides information about the pathophysiology of metachromatic leukodystrophy, the natural progression of symptoms, and how hematopoietic stem cell transplant may work to halt the progression of juvenile metachromatic leukodystrophy. It also focuses on the implications of nursing care, including a review of systems, the need for increased patient and family education, and the complexities of caring for a family with multiple affected children.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17332420     DOI: 10.1177/1043454206298845

Source DB:  PubMed          Journal:  J Pediatr Oncol Nurs        ISSN: 1043-4542            Impact factor:   1.636


  2 in total

1.  Metachromatic Leukodystrophy (MLD): a Pakistani Family with Novel ARSA Gene Mutation.

Authors:  Muhammad Aiman Shahzad; Saba Khaliq; Ali Amar; Saqib Mahmood
Journal:  J Mol Neurosci       Date:  2017-08-10       Impact factor: 3.444

2.  Metachromatic leukodystrophy: Characterization of two (p.Leu433Val, p.Gly449Arg) arylsulfatase A mutations.

Authors:  Yangyang Wang; Xiang Chen; Chan Liu; Shamin Wu; Qingfeng Xie; Quan Hu; Shan Chen; Yiwei Liu
Journal:  Exp Ther Med       Date:  2019-07-09       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.